CEL-SCI Corporation (CVM) is a Biotechnology company in the Healthcare sector, currently trading at $4.36. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Valuation: CVM trades at a trailing Price-to-Earnings (P/E) of -1.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.02.
Net income is $25M (loss), growing at +12.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $9M against $16M equity (Debt-to-Equity (D/E) ratio 0.59, moderate). Current ratio is 2.26 (strong liquidity). Debt-to-assets is 33.3%. Total assets: $28M.
Analyst outlook: 6 / 6 analysts rate CVM as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 80/100 (Pass), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).
